CELERIS THERAPEUTICS
Celeris Therapeutics is an AI-first drug discovery company that develops proximity-inducing compounds (PICs), focusing on PIC degraders for diseases with high unmet medical needs, such as Parkinson's and various types of cancers. Celeris Therapeutics has developed the Celeris One platform to streamline the development of degraders and, most importantly, rationalize their design. Celeris One leverages structure-based geometric deep learning to prioritize specific E3 ligases, design linkers, and ... select the most active compounds for synthesis. An in-house automated lab quickly generates experimental data for additional optimization cycles. Celeris Therapeutics collaborates with pharma and biotech companies to jointly discover and develop small-molecule degrader medicines for all therapeutic areas. It is also developing an in-house drug pipeline. Celeris Therapeutics has offices in Menlo Park, CA, and Graz, Austria.
CELERIS THERAPEUTICS
Industry:
Artificial Intelligence Biotechnology Information Technology Life Science Pharmaceutical
Founded:
2021-01-01
Address:
Menlo Park, California, United States
Country:
United States
Website Url:
http://www.celeristx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
4 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics Font Awesome
Similar Organizations
BenchSci
BenchSci uses machine learning and artificial intelligence to accelerate biomedical discoveries.
Exogene
Exogene is a biotechnology company accelerating target & TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening.
Genesis Therapeutics
Genesis Therapeutics unifies AI and biotech to accelerate the discovery of new medicines
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Numerate
Numerate seeks to overcome major challenges in drug discovery by applying novel machine-learning algorithms, at cloud scale, to drug design.
Protai
Protai is an AI-powered drug discovery startup.
Q-State Biosciences
Q-State has developed world-leading technologies and proprietary approaches for probing rare and genetic CNS conditions.
Spring Discovery
Spring Discovery accelerates the discovery of therapies for aging by targeting the biological processes of aging itself.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Troy Medicare
Troy Medicare is arming independent pharmacies with a health plan and platform tailored to their most vulnerable patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
i&i Prague
i&i Prague investment in Seed Round - Celeris Therapeutics
R42 Group
R42 Group investment in Seed Round - Celeris Therapeutics
APX Ventures
APX Ventures investment in Seed Round - Celeris Therapeutics
Pace Ventures Enigma
Pace Ventures Enigma investment in Seed Round - Celeris Therapeutics
Longevitytech.fund
Longevitytech.fund investment in Seed Round - Celeris Therapeutics
APX Ventures
APX Ventures investment in Pre Seed Round - Celeris Therapeutics
R42 Group
R42 Group investment in Pre Seed Round - Celeris Therapeutics
Longevitytech.fund
Longevitytech.fund investment in Pre Seed Round - Celeris Therapeutics
Official Site Inspections
http://www.celeristx.com
- Host name: dedivirt714.your-server.de
- IP address: 195.201.6.13
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Celeris Therapeutics"
Celeris Therapeutics - Crunchbase Company Profile & Funding
CelerisTx One: A platform that combines AI predictions with high throughput lab automation for the discovery and optimization of protein degrader therapies. Targeted Protein Degradation: …See details»
CelerisTx Company Profile | Management and Employees List
CelerisTx develops the Celeris One platform, a closed-loop discovery engine that predicts biomolecular interactions, generates new chemical entities that mee t relevant degrader …See details»
Celeris Therapeutics - LinkedIn
Celeris Therapeutics is going to solve the R&D shortcomings as the pioneer in AI-driven PIC (proximity-inducing compounds) design using an innovative closed-loop engine (CelerisTx …See details»
CelerisTx - VentureRadar
CelerisTx Follow Following Location: USA. Founded in 2021. Privately Held. Develops innovative, computer-based methods for early-stage drug discovery, targeting undruggable pathogenic …See details»
Celeris Therapeutics | LinkedIn
Celeris Therapeutics | 5.580 Follower:innen auf LinkedIn. The PIC Engineering Company. | Celeris Therapeutics is going to solve the R&D shortcomings as the pioneer in AI-driven PIC …See details»
CelerisTx - Overview, News & Similar companies | ZoomInfo.com
Jan 12, 2024 CelerisTx develops the Celeris One platform, a closed-loop discovery engine that predicts biomolecular interactions, generates new chemical entities that meet relevant …See details»
Celeris Therapeutics - Craft
Celeris Therapeutics is a company that designs proximity-inducing compounds (PICs) to treat diseases. It develops CelerisTx One, a platform for new chemical entities (NCEs) that degrade …See details»
CelerisTx | VentureRadar
Celeris Therapeutics is a tech-enabled early-stage drug discovery company that uses innovative, computer-based methods to develop degrader drugs for... ... Find out ...See details»
Celeris | APEX Ventures
Celeris Therapeutics is a deep learning company that uses innovative, computer-based methods to degrade undruggable targets. Celeris One exploits the potential of degrader technologies …See details»
Celeris Therapeutics to receive 12.5 million Euros in funding from …
Oct 19, 2022 CelerisTx partners with pharma and biotech companies and develops its drug pipeline in neurodegenerative diseases and oncology. The offices are located in Menlo Park, …See details»
Why We Invested in CelerisTx - Medium
Feb 17, 2022 When we at Pace Ventures first met the two founders of CelerisTx, Christopher Trummer and Jakob Hohenberger back in May 2021, leveraging AI models for protein …See details»
Celeris Therapeutics, the Pioneer in AI-driven Degrader Design, …
Nov 1, 2021 Adds ~25 new jobs, building on 20 created in 2021. Increases capacity and efficiency of AI-based drug discovery capabilities in chemistry and biology.See details»
Celeris Therapeutics GmbH. (4/4/22). "Press Release: Celeris ...
Boehringer Ingelheim leverages CelerisTx’s proprietary AI-based platform to generate novel proximity-inducing compounds to degrade pathogenic proteins CelerisTx, a biopharmaceutical …See details»
Celeris Therapeutics: AI-driven protein degradation
CelerisTx is a global acting biotech company with promising assets and results. CelerisTx uses AI-driven technologies to design molecules to degrade proteins that cause diseases like …See details»
CelerisTx announces $4.4m financing to advance pipeline of
Feb 10, 2022 CelerisTx is already collaborating with several big pharma companies and runs three drug discovery programs covering the indications of Parkinson’s and various types of …See details»
Celeris Therapeutics and Boehringer Ingelheim enter ... - BioSpace
Menlo Park, CA, April 5, 2022 -- Boehringer Ingelheim leverages CelerisTx’s proprietary AI-based platform to generate novel proximity-inducing compounds to degrade pathogenic proteins …See details»
CelerisTx in a $4.4 million seed funding round backed by
Company: CelerisTx. Industry: Biotech Health services. Related deals Biolux Technology raised CHF 4 million is a seed funding raised from redalpine and Revere Partners. Health services …See details»
CelerisTx: Drug Discovery for Incurable Diseases with ML on AWS
Celeris Therapeutics (CelerisTx) is pioneering the adoption of AI on PICs, focusing on Targeted Protein Degradation. In terms of data, in protein degradation, that means identifying multiple …See details»
CelerisTx in research collaboration with Merck KGaA
Feb 9, 2022 CelerisTx’s technology enables faster discovery and design of bifunctional degraders MENLO PARK, CA, USA I February 9, 2022 I CelerisTx today announced a …See details»
CelerisTx in research collaboration with Merck KGaA, Darmstadt, …
CelerisTx, "AI is increasingly important to identify hidden relationships in large target-ligand chemical spaces. With Merck KGaA, Darmstadt, Germany’s experience in drug discovery …See details»